The Swiss drugmaker conducted two identically designed studies, each involving around 1,000 participants, which were reviewed by doctors for more than two years. In each study, volunteers were randomly assigned to receive gantirumab and some to receive gantirumab medicinal fictional.
The company said, in a statement, that the drug was associated with a relative decrease in spoilage symptoms About 8% in one of the two studies and 6% in the other study comparing those who received the drug and those who were given a placebo, but he added that these results are not statistically significant.
Roche shares fell 4.4% to a low in about seven weeks.
My company’s stock has gone up "Biogenic" And"Eli Lilly" Industry of the Americas pharmaceutical They are developing competing treatments for Alzheimer’s disease, growing 3.8% and 2.3% respectively in premarket trade.
In September, Biogen had surprising success with an experimental Alzheimer’s disease drug it had developed with Essay.
The two companies said, at the time, that their experimental drug "Licanim" It slowed the progression of Alzheimer’s disease by 27% compared to a placebo in a large study of patients in the early stages of symptom onset.
“>
Roche said in a statement on Monday that the two studies, conducted together, fell short of their desired goal of showing that the drug “Gantirumab” can preserve skills such as memory, problem solving, orientation and personal care in patients in the early stages of the disease. Alzheimers.
The Swiss drugmaker conducted two identical studies, each involving around 1,000 participants, which were reviewed by doctors over two years. In each study, volunteers were randomly assigned to receive gantirumab and some to receive gantirumab medicinal fictional.
The company said, in a statement, that the drug was associated with a relative decrease in spoilage symptoms By about 8 percent in one of the two studies and 6 percent in the other study comparing those who received the drug and those who were given a placebo, but he added that these results are not statistically significant.
Roche shares fell 4.4% to a low in about seven weeks.
The shares of the American companies “Biogen” and “Eli Lilly” have risen pharmaceutical They are developing competing treatments for Alzheimer’s disease, growing 3.8% and 2.3% respectively in premarket trade.
In September, Biogen had surprising success with an experimental Alzheimer’s disease drug it had developed with Essay.
At the time, the companies said their investigational drug, licanimab, slowed the progression of Alzheimer’s disease by 27 percent compared with a placebo in a large study of patients in the early stages of symptom onset.
